Drug Trial Radar · NCT07674823
Study Of KITE-753 in R/R B-Cell ALL
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Apr 1, 2029
Study completion Apr 1, 2031
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kite, A Gilead Company
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
Conditions
- B-cell Acute Lymphoblastic Leukemia
Interventions
KITE-753Drug
Given by infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Adverse Events (AEs)Time frame: Through study completion; an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.